相关实验视频
Updated: Sep 14, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.1K
在CYP2C19的功能丧失携带者中,因年龄和功能分层的中风或TIA:CHANCE-2试验替代研究中,蒂卡格勒勒与克洛皮多格勒对比
Yu Wu1, Yilun Zhou1, Yuesong Pan2,3
1Department of Nephrology, BeijingTiantan Hospital, Capital Medical University, Beijing, China.
Renal failure
|July 23, 2025
概括
在正常功能的CYP2C19功能丧失载体中,提卡格勒减少了中风风险,超过了克洛皮多格勒. 较年轻的患者和患有功能不全的患者在服用提卡格时经历了更多的出血事件.
科学领域:
- 心脏病学 心脏病学
- 药物基因组学 药物基因组学
- 神经学 神经学
背景情况:
- 患有CYP2C19功能丧失 (LOF) 遗传变异的中风患者经常接受抗血小板治疗.
- 在LOF载体中,由于激活受损,克洛皮多格勒的疗效可能会降低.
- 提卡格勒勒提供了一个替代品,因为它不需要代谢激活.
研究的目的:
- 在中风患者中比较蒂卡格雷勒与克洛皮多格雷尔的疗效和安全性,这些患者是CYP2C19 LOF载体.
- 以患者年龄和功能 (eGFR) 来分层治疗效果.
主要方法:
- 在CHANCE-2试验中,患者被随机分配给提卡格雷罗-阿司匹林或克洛皮多格雷尔-阿司匹林.
- 主要结局是90天内再次中风;通过出血事件评估安全性.
- 患者按年龄 (<65岁与≥65岁) 和eGFR水平分层.
主要成果:
- 与克洛皮多格雷尔-阿司匹林相比,在两个年龄组的EGFR>90mL/min/1.73m2的患者中,蒂卡格雷勒-阿司匹林显著降低了中风风险 (p<0.05).
- 在 eGFR 60-89 mL/min/1.73 m2 的患者中,在提卡格雷勒和克洛皮多格雷尔之间没有观察到中风减少的显著差异.
- 在正常功能的年轻患者和功能受损的老年患者中,提卡格雷勒-阿司匹林可增加轻度出血.
结论:
- 具有正常功能,携带CYP2C19 LOF变异的老年中风患者可能比克洛皮多格雷尔更受益于提卡格雷罗.
- 由于出血风险增加,在这个人群中使用提卡格勒需要仔细考虑,特别是在具有正常功能的年轻患者和患有功能不全的老年患者中.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
646
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
646
Coronary Artery Disease V: Interprofessional Care
33
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
33
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
120
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
120
Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
684
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
684

